Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment

Caroline Seymour
Published: Friday, Mar 23, 2018

Chloe E. Atreya, MD, PhD

Chloe E. Atreya, MD, PhD
Combination immunotherapy has shown great promise in patients with metastatic colorectal cancer (mCRC), specifically in the CheckMate-142 study in which nivolumab (Opdivo) plus ipilimumab (Yervoy) yielded a 55% overall response rate and 80% disease control rate in patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

State of the Science Summit™ on Gastrointestinal Cancers, Atreya, an assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

OncLive: What are some recent developments in the mCRC landscape?

Atreya: I focused on sidedness and maintenance strategies for specific subgroups, including patients with MSI-H and BRAF-mutated CRC. With sidedness, I gave an overview of recent research, including Study 80405. I highlighted the NCCN guidelines, which state that EGFR-targeted antibodies are an option for patients with left-sided RAS wild-type tumors. These antibodies should not be considered for patients who have RAS-mutated tumors or right-sided tumors in the first-line setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication